Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67
Tóm tắt
Hepatoma-derived growth factor (HDGF) has been verified to serve as a credible prognostic marker for several types of cancers, but its role in urologic carcinomas remains undetermined. In this study, we analyzed the significance of HDGF, as well as its relative factors such as vascular endothelial growth factor-A (VEGF-A) and Ki-67, in penile squamous cell carcinoma (PSCC). Formalin-fixed paraffin-embedded PSCC samples from 54 patients receiving surgery at Qilu Hospital of Shandong University were included in the retrospective study. The expressions of HDGF, VEGF-A, and Ki-67 were detected by immunohistochemistry of a non-biotin polymerized horseradish peroxidase method. The relationships between the expressions of HDGF and VEGF-A, Ki-67 were assessed. Moreover, their correlations with clinical pathologic characteristics and disease prognosis were, respectively, evaluated. HDGF, VEGF-A, and Ki-67 were positively expressed in 28 (51.9 %), 29 (53.7 %), and 26 (48.1 %) patients, respectively. The expressions of VEGF-A and Ki-67 were closely correlated with PSCC type (P < 0.05). A statistically significant relationship between the expressions of HDGF and VEGF-A in PSCC was observed (P = 0.03). Patients with symptom interval of more than 6 months had a significantly poorer survival rate than those with symptom interval less than 6 months (43.3 vs. 70.8 %, P = 0.043). Patients with positive HDGF expression also showed a significantly poorer survival rate than those with negative HDGF expression (39.3 vs. 73.1 %, P = 0.013). Logistic regression demonstrated that the expression level of HDGF was an independent predictor for the prognosis of postoperative patients. The expression of HDGF significantly correlated with VEGF-A, but not Ki-67 expression. Overexpression of HDGF, rather than VEGF-A or Ki-67, was confirmed to be an independent prognosticator of poor outcome for PSCC patients.
Tài liệu tham khảo
Frisch M, Friis S, Kjaer SK, Melbye M. Falling incidence of penis cancer in an uncircumcised population (Denmark 1943–1990). BMJ. 1995;311(7018):1471.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. doi:10.3322/caac.20073.
Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer. 2000;82(9):1585–92. doi:10.1054/bjoc.1999.1071.
Bleeker MCG, Heideman DAM, Snijders PJF, Horenblas S, Dillner J, Meijer CJLM. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol. 2009;27(2):141–50. doi:10.1007/s00345-008-0302-z.
Verhoeven RH, Janssen-Heijnen ML, Saum KU, Zanetti R, Caldarella A, Holleczek B, et al. Population-based survival of penile cancer patients in Europe and the United States of America: no improvement since 1990. Eur J Cancer. 2013;49(6):1414–21. doi:10.1016/j.ejca.2012.10.029.
Di Lorenzo G, Perdonà S, Buonerba C, Sonpavde G, Gigantino V, Pannone G, et al. Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. J Transl Med. 2013;11(1):161. doi:10.1186/1479-5876-11-161.
Gou HF, Li X, Qiu M, Cheng K, Li LH, Dong H, et al. Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma. PLoS One. 2013;8(4):e62175. doi:10.1371/journal.pone.0062175.
Masferrer E, Ferrándiz-Pulido C, Lloveras B, Masferrer-Niubò M, Espinet B, Salido M, et al. MYC copy number gains are associated with poor outcome in penile squamous cell carcinoma. J Urol. 2012;188(5):1965–71. doi:10.1016/j.juro.2012.07.003.
Ferrandiz-Pulido C, Masferrer E, Toll A, Hernandez-Losa J, Mojal S, Pujol RM, et al. mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E overexpression correlate with aggressive tumoral behavior. J Urol. 2013;. doi:10.1016/j.juro.2013.06.015.
De Paula AA, Motta ED, Alencar RC, Saddi VA, da Silva RC, Caixeta GN, et al. The impact of cyclooxygenase-2 and vascular endothelial growth factor C immunoexpression on the prognosis of penile carcinoma. J Urol. 2012;187(1):134–40. doi:10.1016/j.juro.2011.09.027.
Nakamura H, Kambe H, Egawa T, Kimura Y, Ito H, Hayashi E, et al. Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta. 1989;183(3):273–84.
Nakamura H, Izumoto Y, Kambe H, Kuroda T, Mori T, Kawamura K, et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem. 1994;269(40):25143–9.
Everett AD, Stoops T, McNamara CA. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem. 2001;276(40):37564–8. doi:10.1074/jbc.M105109200.
Everett AD, Bushweller J. Hepatoma derived growth factor is a nuclear targeted mitogen. Curr Drug Targets. 2003;4(5):367–71.
Kishima Y, Yamamoto H, Izumoto Y, Yoshida K, Enomoto H, Yamamoto M, et al. Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem. 2002;277(12):10315–22. doi:10.1074/jbc.M111122200.
Liu YF, Zhao R, Guo S, Wang XQ, Lian PL, Chen YG, et al. Expression and clinical significance of hepatoma-derived growth factor as a prognostic factor in human hilar cholangiocarcinoma. Ann Surg Oncol. 2011;18(3):872–9. doi:10.1245/s10434-010-1303-x.
Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang B, Hoshida Y, et al. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res. 2006;12(20 Pt 1):6043–8. doi:10.1158/1078-0432.CCR-06-1064.
Lin YW, Li CF, Chen HY, Yen CY, Lin LC, Huang CC, et al. The expression and prognostic significance of hepatoma-derived growth factor in oral cancer. Oral Oncol. 2012;48(7):629–35. doi:10.1016/j.oraloncology.2012.01.014.
Tsai HE, Wu JC, Kung ML, Liu LF, Kuo LH, Kuo HM, et al. Up-regulation of hepatoma-derived growth factor facilities tumor progression in malignant melanoma. PLoS One. 2013;8(3):e59345. doi:10.1371/journal.pone.0059345.
Hu TH, Huang CC, Liu LF, Lin PR, Liu SY, Chang HW, et al. Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer. 2003;98(7):1444–56. doi:10.1002/cncr.11653.
Zhang J, Ren H, Yuan P, Lang W, Zhang L, Mao L. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res. 2006;66(1):18–23. doi:10.1158/0008-5472.CAN-04-3905.
Iwasaki T, Nakagawa K, Nakamura H, Takada Y, Matsui K, Kawahara K. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol Rep. 2005;13(6):1075–80.
Guo Z, He Y, Wang S, Zhang A, Zhao P, Gao C, et al. Various effects of hepatoma-derived growth factor on cell growth, migration and invasion of breast cancer and prostate cancer cells. Oncol Rep. 2011;26(2):511–7. doi:10.3892/or.2011.1295.
Zhang A, Long W, Guo Z, Cao BB. Downregulation of hepatoma-derived growth factor suppresses the malignant phenotype of U87 human glioma cells. Oncol Rep. 2012;28(1):62–8. doi:10.3892/or.2012.1768.
Li M, Shen J, Wu X, Zhang B, Zhang R, Weng H, et al. Downregulated expression of hepatoma-derived growth factor (HDGF) reduces gallbladder cancer cell proliferation and invasion. Med Oncol. 2013;30(2):587. doi:10.1007/s12032-013-0587-7.
Li SZ, Zhao YB, Cao WD, Qu Y, Luo P, Zhen HN, et al. The expression of hepatoma-derived growth factor in primary central nervous system lymphoma and its correlation with angiogenesis, proliferation and clinical outcome. Med Oncol. 2013;30(3):622. doi:10.1007/s12032-013-0622-8.
Broders AC. Squamous-cell epithelioma of the skin: a study of 256 cases. Ann Surg. 1921;73(2):141–60.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
Rocha RM, Miller K, Soares F, Schenka N, Vassallo J, Gobbi H. Biotin-free systems provide stronger immunohistochemical signal in oestrogen receptor evaluation of breast cancer. J Clin Pathol. 2009;62(8):699–704. doi:10.1136/jcp.2009.065326.
Stankiewicz E, Ng M, Cuzick J, Mesher D, Watkin N, Lam W, et al. The prognostic value of Ki-67 expression in penile squamous cell carcinoma. J Clin Pathol. 2012;65(6):534–7. doi:10.1136/jclinpath-2011-200638.
Papadopoulos O, Betsi E, Tsakistou G, Frangoulis M, Fangoulis M, Kouvatseas G, et al. Expression of cyclin D1 and Ki-67 in squamous cell carcinoma of the penis. Anticancer Res. 2007;27(4B):2167–74.
Yano T, Tanikawa S, Fujie T, Masutani M, Horie T. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer. 2000;36(5):601–9.
Wanschura S, Schoenmakers EF, Huysmans C, Bartnitzke S, Van de Ven WJ, Bullerdiek J. Mapping of the gene encoding the human hepatoma-derived growth factor (HDGF) with homology to the high-mobility group (HMG)-1 protein to Xq25. Genomics. 1996;32(2):298–300. doi:10.1006/geno.1996.0122.
Yang J, Everett AD. Hepatoma-derived growth factor binds DNA through the N-terminal PWWP domain. BMC Mol Biol. 2007;8:101. doi:10.1186/1471-2199-8-101.
Bourgade V, Drouin SJ, Yates DR, Parra J, Bitker MO, Cussenot O, et al. Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival. World J Urol. 2013;. doi:10.1007/s00345-013-1045-z.
Okuda Y, Nakamura H, Yoshida K, Enomoto H, Uyama H, Hirotani T, et al. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci. 2003;94(12):1034–41.
Kung ML, Tsai HE, Hu TH, Kuo HM, Liu LF, Chen SC, et al. Hepatoma-derived growth factor stimulates podosome rosettes formation in NIH/3T3 cells through the activation of phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun. 2012;425(2):169–76. doi:10.1016/j.bbrc.2012.07.060.
Mao J, Xu Z, Fang Y, Wang H, Xu J, Ye J, et al. Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci. 2008;99(11):2120–7. doi:10.1111/j.1349-7006.2008.00928.x.
Martins ACP, Britto S, Takata C, Suaid HJ, Cologna AJ, Tucci S Jr, et al. VEGF immunoexpression in penile carcinoma. Acta Cirurgica Brasileira. 2002;17:52–4.
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133(4):1710–5.
Protzel C, Knoedel J, Zimmermann U, Woenckhaus C, Poetsch M, Giebel J. Expression of proliferation marker Ki67 correlates to occurrence of metastasis and prognosis, histological subtypes and HPV DNA detection in penile carcinomas. Histol Histopathol. 2007;22(11):1197–204.
Lopes A, Bezerra AL, Pinto CA, Serrano SV, de MellO CA, Villa LL. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. J Urol. 2002;168(1):81–6.
Gunia S, Erbersdobler A, Hakenberg OW, Koch S, May M. p16(INK4a) is a marker of good prognosis for primary invasive penile squamous cell carcinoma: a multi-institutional study. J Urol. 2012;187(3):899–907. doi:10.1016/j.juro.2011.10.149.
Leijte JA, Valdés Olmos RA, Nieweg OE, Horenblas S. Anatomical mapping of lymphatic drainage in penile carcinoma with SPECT-CT: implications for the extent of inguinal lymph node dissection. Eur Urol. 2008;54(4):885–90. doi:10.1016/j.eururo.2008.04.094.
Leijte JA, Kroon BK, Valdés Olmos RA, Nieweg OE, Horenblas S. Reliability and safety of current dynamic sentinel node biopsy for penile carcinoma. Eur Urol. 2007;52(1):170–7. doi:10.1016/j.eururo.2007.01.107.
Sadeghi R, Gholami H, Zakavi SR, Kakhki VR, Tabasi KT, Horenblas S. Accuracy of sentinel lymph node biopsy for inguinal lymph node staging of penile squamous cell carcinoma: systematic review and meta-analysis of the literature. J Urol. 2012;187(1):25–31. doi:10.1016/j.juro.2011.09.058.
Ayyappan K, Ananthakrishnan N, Sankaran V. Can regional lymph node involvement be predicted in patients with carcinoma of the penis? Br J Urol. 1994;73(5):549–53.